Angiodynamics Stock Earnings Reports

AngioDynamics reported a strong fiscal Q2 2026 with pro forma revenue up 8.8% to $79.4M (Med Tech +13%, Med Device +5.6%). Key growth drivers included Auryon (18th consecutive quarter of double-digit growth; Auryon revenue +18.6%), continued momentum in AlphaVac (sequential and double‑digit Y/Y growth for that product line), record NanoKnife prostate procedure volume (NanoKnife revenue +22.2%) and international capital sales tied to a distribution transaction in France. The company achieved several regulatory milestones for its mechanical thrombectomy portfolio: IDE approvals for the APEX-Return (AlphaReturn blood management) and PAVE (AngioVac for right‑sided infective endocarditis) studies, plus a 510(k) clearance expanding AlphaVac F18 85 indications. Financially, gross margin improved to 56.4% (+170 bps Y/Y), adjusted EBITDA nearly doubled to $5.9M, adjusted net loss narrowed to $0.1M (adj. loss/share $0.10), and cash was $41.6M. Management raised full‑year fiscal 2026 guidance: revenue to $312–314M (up from $308–313M) and adjusted EBITDA to $8–10M (from $6–10M). They reiterated gross margin guidance (53.5%–55.5%), expect full‑year tariff expense of $4–6M, and continue to target ~10% of sales for R&D. CEO James (Jim) Clemmer announced his intent to retire, with a Board search for a successor during fiscal 2027; he will remain until a transition is complete. Lastly, the Federal Circuit affirmed a prior decision in the Bard patent litigation, eliminating a potential $3M settlement payment. Overall, the quarter demonstrates simultaneous revenue growth and improved profitability, continued clinical/regulatory progress (which could expand addressable markets), and cash generation, while management balances near‑term investments with margin improvement initiatives.